TrialHaematologica2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Benjamin Hanfstein et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
59 papers cite it
this paperpooled ittrialcites it